Drug Trial Radar · NCT02189629
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
Last checked: Nov 19, 2026Latest source record: Nov 14, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
453
Actual
Start
Feb 23, 2015
Primary completion
Feb 23, 2017
Study completion Feb 23, 2017
Sponsor
- Lead sponsor
- Galderma R&DIndustry
- Sponsor type
- Industry
- First posted
- Jul 14, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 9 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multi-center, open-label, non-comparative safety and efficacy study with 52 Weeks of treatment on the face and trunk for acne vulgaris.
Conditions
- Acne Vulgaris
Interventions
CD5789 (trifarotene)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Investigator Global Assessment (IGA) Success Rate up to Week 52Time frame: From Baseline to Week 52
Locations
32 sites in 4 countries. Site status is shown where the registry gives one.
Galderma Investigational Site
Mobile, Alabama
Galderma Investigational Site
Rogers, Arkansas
Galderma Investigational Site
Sacramento, California
Galderma Investigational Site
San Diego, California
Galderma Investigational Site
Miami, Florida
Galderma Investigational Site
Miramar, Florida
Galderma Investigational Site
Newnan, Georgia
Galderma Investigational Site
Louisville, Kentucky
Galderma Investigational Site
Albuquerque, New Mexico
Galderma Investigational Site
New York, New York
Galderma Investigational Site
High Point, North Carolina
Galderma Investigational Site
Beachwood, Ohio
Galderma Investigational Site
Portland, Oregon
Galderma Investigational Site
Knoxville, Tennessee
Galderma Investigational Site
Chomutov, Czechia
Galderma Investigational site
Hradec Králové, Czechia
Galderma Investigational Site
Olomouc, Czechia
Galderma Investigational Site
Pardubice, Czechia
Galderma Investigational site
Prague, Czechia
Galderma Investigational Site
Augsburg, Germany
Galderma Investigational Site
Berlin, Germany
Galderma Investigational Site
Berlin, Germany
Galderma Investigational Site
Dessau, Germany
Galderma Investigational Site
Mahlow, Germany
Galderma Investigational Site
Münster, Germany
Galderma Investigational Site
Wuppertal, Germany
Galderma Investigational Site
Balatonfüred, Hungary
Galderma Investigational Site
Miskolc, Hungary
Galderma Investigational Site
Pécel, Hungary
Galderma Investigational Site
Szeged, Hungary
Galderma Investigational Site
Szekszárd, Hungary
Galderma Investigational Site
Szolnok, Hungary
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.